Demographic Trends in HIV-Infected Youth

Changing Landscape of HIV Infection

Recent observations highlight a demographic shift among babies born with HIV, indicating a noticeable gap between those born in earlier years and more recent births. Older HIV-positive patients face heightened risks associated with viral load in their blood, immunosuppression, severe clinical events, and increased mortality rates when compared to their younger counterparts. This disparity can be attributed to advancements in treatment options that now begin at an earlier age.

Advancements in Treatment

Current antiretroviral (ARV) and combination antiretroviral therapy (cART) have significantly improved the longevity and quality of life for individuals living with HIV. These therapies have not only reduced the rates of mother-to-child transmission but have also fostered a new demographic of young individuals receiving treatment from an early age.

Defining Perinatally HIV-Infected Youth

Perinatally HIV-infected youth (PHIVY) can be categorized into two primary age groups: 7-12 years and 13-30 years. In a recent study, participants were included if they had at least one hospital visit, one white blood cell count, or viral load measurement following their initial assessment.

Study Objectives and Methodology

The study aimed to explore the relationship between age, white blood cell count, viral load, and ARV drug use in relation to severe clinical events and mortality as PHIVY transition into adulthood. Researchers analyzed data from the Pediatric HIV/AIDS Cohort Study (PHACS) Adolescent Master Protocol (AMP) and the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT), involving 1,446 participants aged between 7 and 30 years. Participants were evaluated based on their ARV treatment, white blood cell counts, and viral load during follow-up hospital visits.

Clinical Event Analysis

The rates of clinical events were categorized by age groups, white blood cell counts, viral load, and therapy status. Furthermore, these clinical events were classified according to severity, referencing the Centers for Disease Control and Prevention (CDC) stages B and C.

Findings on Older PHIVY

The study revealed that older PHIVY, specifically those aged 18-30 years, exhibited a greater risk of elevated blood viral loads, lower white blood cell counts, and more severe clinical events classified as CDC-B and CDC-C. The observed higher viral load levels may be linked to inconsistent medication adherence or the cumulative effects of viral load over time. Additionally, older PHIVY began their combination antiretroviral therapy later and spent extended periods with lower white blood cell counts (below 200/µl).

Impact of Combination Antiretroviral Therapy

Conversely, the use of cART was associated with a reduction in clinical events and mortality rates. The authors concluded that antiretroviral therapy is instrumental in suppressing severe clinical events, opportunistic infections, and death. However, they noted that viral load, lower white blood cell counts, and rates of clinical events and mortality tended to increase throughout adolescence and into young adulthood.

Implications for Future Care

These findings underscore the critical need for improved adherence to antiretroviral therapy for PHIVY, starting in adolescence and continuing through adulthood, to enhance long-term health outcomes.

Study Limitations

It is important to note that the representation of the 7-12 age group was less comprehensive compared to other demographics, and the presence of two different data collection protocols may have influenced the rate estimates.

Author Information

Written by: Kenneth Dominguez, PhD